CN103819490B - 一种头孢呋辛钠化合物 - Google Patents
一种头孢呋辛钠化合物 Download PDFInfo
- Publication number
- CN103819490B CN103819490B CN201410105896.XA CN201410105896A CN103819490B CN 103819490 B CN103819490 B CN 103819490B CN 201410105896 A CN201410105896 A CN 201410105896A CN 103819490 B CN103819490 B CN 103819490B
- Authority
- CN
- China
- Prior art keywords
- cefuroxime sodium
- crystalline compounds
- preparation
- cefuroxime
- cephalofruxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000003388 sodium compounds Chemical class 0.000 title claims abstract description 38
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 239000002245 particle Substances 0.000 claims abstract description 9
- 229910017488 Cu K Inorganic materials 0.000 claims abstract description 8
- 229910017541 Cu-K Inorganic materials 0.000 claims abstract description 8
- 230000005260 alpha ray Effects 0.000 claims abstract description 8
- 238000005259 measurement Methods 0.000 claims abstract description 8
- 238000000634 powder X-ray diffraction Methods 0.000 claims abstract description 8
- URDOHUPGIOGTKV-JTBFTWTJSA-M Cefuroxime sodium Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 URDOHUPGIOGTKV-JTBFTWTJSA-M 0.000 claims description 53
- 229960000534 cefuroxime sodium Drugs 0.000 claims description 53
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 30
- 239000012046 mixed solvent Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- 239000000243 solution Substances 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 12
- 238000010792 warming Methods 0.000 claims description 10
- 238000005406 washing Methods 0.000 claims description 8
- 238000001816 cooling Methods 0.000 claims description 6
- 239000012043 crude product Substances 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 5
- 238000000034 method Methods 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000011282 treatment Methods 0.000 description 8
- 238000004090 dissolution Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 229960001668 cefuroxime Drugs 0.000 description 6
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 238000004806 packaging method and process Methods 0.000 description 5
- 238000005070 sampling Methods 0.000 description 5
- 238000007789 sealing Methods 0.000 description 5
- 238000004088 simulation Methods 0.000 description 5
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000013557 residual solvent Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- OEOIWYCWCDBOPA-UHFFFAOYSA-N 6-methyl-heptanoic acid Chemical compound CC(C)CCCCC(O)=O OEOIWYCWCDBOPA-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229960005475 antiinfective agent Drugs 0.000 description 1
- 210000001742 aqueous humor Anatomy 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- -1 methoxyimino Chemical group 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000012429 reaction media Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- NGSFWBMYFKHRBD-UHFFFAOYSA-N sodium;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O NGSFWBMYFKHRBD-UHFFFAOYSA-N 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/14—Compounds having a nitrogen atom directly attached in position 7
- C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
- C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
- C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
- C07D501/26—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group
- C07D501/34—Methylene radicals, substituted by oxygen atoms; Lactones thereof with the 2-carboxyl group with the 7-amino radical acylated by carboxylic acids containing hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
- C07D501/02—Preparation
- C07D501/12—Separation; Purification
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Cephalosporin Compounds (AREA)
Abstract
Description
批次 | 1 | 2 | 3 | 4 | 5 | 平均值 |
θ(°) | 30 | 28 | 29 | 30 | 29 | 29.2 |
批次 | 1 | 2 | 3 | 4 | 5 | 平均值 |
秒 | 12 | 13 | 13 | 12 | 13 | 12.6 |
实施例1 | 对比例1 | 对比例2 | 对比例3 | 对比例4 | |
混合溶剂与头孢呋辛钠水溶液体积比 | 10:1 | 5:1 | 3:1 | 15:1 | 20:1 |
收率 | 95.6% | 91.5% | 85.1% | 81.2% | 76.2% |
纯度 | 99.9% | 98.2% | 97.5% | 98.1% | 95.2% |
实施例1 | 对比例5 | 对比例6 | 对比例7 | 对比例8 | |
混合溶剂加入速度(毫升/分钟) | 100 | 50 | 30 | 200 | 300 |
收率 | 95.6% | 92.7% | 88.2% | 84.6% | 81.7% |
纯度 | 99.9% | 99.1% | 96.3% | 97.8% | 96.3% |
治疗方案 | n | 痊愈 | 显效 | 好转 | 无效 | 痊愈率(%) | 总有效率(%) |
对照组 | 100 | 54 | 24 | 18 | 5 | 64 | 78% |
实验组 | 100 | 79 | 13 | 7 | 1 | 79 | 92% |
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410105896.XA CN103819490B (zh) | 2014-03-20 | 2014-03-20 | 一种头孢呋辛钠化合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410105896.XA CN103819490B (zh) | 2014-03-20 | 2014-03-20 | 一种头孢呋辛钠化合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103819490A CN103819490A (zh) | 2014-05-28 |
CN103819490B true CN103819490B (zh) | 2016-03-30 |
Family
ID=50754818
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410105896.XA Active CN103819490B (zh) | 2014-03-20 | 2014-03-20 | 一种头孢呋辛钠化合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103819490B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105884799A (zh) * | 2015-09-23 | 2016-08-24 | 石药集团中诺药业(石家庄)有限公司 | 一种新的头孢呋辛钠化合物 |
CN107586304A (zh) * | 2017-07-14 | 2018-01-16 | 浙江永宁药业股份有限公司 | 一种头孢呋辛钠晶体化合物及其制备方法 |
CN110437258A (zh) * | 2019-08-12 | 2019-11-12 | 上海龙翔生物医药开发有限公司 | 头孢呋辛钠的制备方法及其应用 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235896B1 (en) * | 1998-03-30 | 2001-05-22 | Ranbaxy Laboratories Limited | Process for the preparation of cefuroxime |
WO2004050663A2 (en) * | 2002-12-05 | 2004-06-17 | Orchid Chemicals & Pharmaceuticals Ltd | An improved process for the preparation of cefuroxime sodium |
CN101967156A (zh) * | 2010-09-26 | 2011-02-09 | 石药集团石家庄高科医药科技开发有限公司 | 一种头孢呋辛钠重结晶的方法 |
CN102746323A (zh) * | 2012-06-26 | 2012-10-24 | 天津大学 | 一种头孢呋辛酸的新晶型及其结晶制备方法 |
CN102838622A (zh) * | 2011-06-21 | 2012-12-26 | 国药集团威奇达药业有限公司 | 稳定的头孢呋新钠的制备方法 |
CN103102357A (zh) * | 2013-02-21 | 2013-05-15 | 广东立国制药有限公司 | 一种头孢呋辛钠的合成方法 |
-
2014
- 2014-03-20 CN CN201410105896.XA patent/CN103819490B/zh active Active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235896B1 (en) * | 1998-03-30 | 2001-05-22 | Ranbaxy Laboratories Limited | Process for the preparation of cefuroxime |
WO2004050663A2 (en) * | 2002-12-05 | 2004-06-17 | Orchid Chemicals & Pharmaceuticals Ltd | An improved process for the preparation of cefuroxime sodium |
CN101967156A (zh) * | 2010-09-26 | 2011-02-09 | 石药集团石家庄高科医药科技开发有限公司 | 一种头孢呋辛钠重结晶的方法 |
CN102838622A (zh) * | 2011-06-21 | 2012-12-26 | 国药集团威奇达药业有限公司 | 稳定的头孢呋新钠的制备方法 |
CN102746323A (zh) * | 2012-06-26 | 2012-10-24 | 天津大学 | 一种头孢呋辛酸的新晶型及其结晶制备方法 |
CN103102357A (zh) * | 2013-02-21 | 2013-05-15 | 广东立国制药有限公司 | 一种头孢呋辛钠的合成方法 |
Non-Patent Citations (1)
Title |
---|
头孢呋辛钠耦合结晶新工艺研究;赵颖颖;《中国博士学位论文全文数据库工程科技I辑》;20120715(第7期);正文第98-100页溶析剂、第101页文字部分 * |
Also Published As
Publication number | Publication date |
---|---|
CN103819490A (zh) | 2014-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103641822B (zh) | 一种卡格列净化合物及其药物组合物 | |
CN102875574A (zh) | 头孢曲松钠晶型及其制备方法 | |
CN103819490B (zh) | 一种头孢呋辛钠化合物 | |
CN104402902A (zh) | 手性7-(哌嗪取代的吡唑醛缩异烟肼腙)氟喹诺酮羧酸衍生物及其制备方法和应用 | |
CN103102357B (zh) | 一种头孢呋辛钠的合成方法 | |
CN102875531B (zh) | 一种(r)-兰索拉唑无水晶型及其制备方法 | |
CN104910186B (zh) | 一种头孢硫脒化合物 | |
US8853389B2 (en) | Process for refining cefmetazole sodium | |
US20170158711A1 (en) | Novel industrial crystallization method of cefuroxime sodium and preparation thereof | |
CN102643255A (zh) | 一种炎琥宁化合物 | |
CN104341435B (zh) | 头孢曲松钠的精制方法 | |
CN102351812B (zh) | 甲磺酸桂哌齐特晶型iii及其制备方法 | |
CN106038482A (zh) | 一种恩诺沙星子宫灌注液及其制备方法和应用 | |
CN107235925B (zh) | 抑制多重耐药菌的化合物、其制备方法及应用 | |
CN103951679A (zh) | 一种头孢哌酮钠化合物及其药物组合物 | |
CN106478636B (zh) | 替格瑞洛晶型及制备方法 | |
CN101143871B (zh) | 头孢菌素衍生物 | |
CN101367800A (zh) | 抗结核杆菌药物3-烷氧基-8-烷基-12-r3-药根碱盐的合成方法及应用 | |
US20140121369A1 (en) | Method for purifying ceftizoxime sodium | |
CN103910750B (zh) | 一种头孢唑肟钠化合物 | |
CN101768172A (zh) | 用于抗感染的普卢利沙星的光学活性化合物和制备方法 | |
CN104829467A (zh) | 盐酸氨溴索二水化合物 | |
CN103242363A (zh) | 氟苯尼考磷酸二酯及盐及其制备方法 | |
CN103159649A (zh) | 磺酰胺类化合物的制备及其应用 | |
CN106397412A (zh) | 5‑羟色胺受体激动剂及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160617 Address after: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Patentee after: YOUCARE PHARMACEUTICAL GROUP Co.,Ltd. Patentee after: Beijing Yuekangyuantong Pharmaceutical Co.,Ltd. Address before: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Patentee before: YOUCARE PHARMACEUTICAL GROUP Co.,Ltd. |
|
CB03 | Change of inventor or designer information |
Inventor after: Li Qi Inventor after: Zhang Qibo Inventor after: Yang Lei Inventor before: Li Qi Inventor before: Yang Lei |
|
CB03 | Change of inventor or designer information | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Co-patentee after: Beijing Yuekangyuantong Pharmaceutical Co.,Ltd. Patentee after: Yuekang Pharmaceutical Group Co.,Ltd. Address before: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Co-patentee before: Beijing Yuekangyuantong Pharmaceutical Co.,Ltd. Patentee before: YOUCARE PHARMACEUTICAL GROUP Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Co-patentee after: Beijing Yuantong Kangbai Pharmaceutical Co.,Ltd. Patentee after: Yuekang Pharmaceutical Group Co.,Ltd. Address before: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Co-patentee before: Beijing Yuekangyuantong Pharmaceutical Co.,Ltd. Patentee before: Yuekang Pharmaceutical Group Co.,Ltd. |
|
CP01 | Change in the name or title of a patent holder | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200619 Address after: 100176 Beijing city Hondar Daxing District economic and Technological Development Zone, Road No. 6 Patentee after: Yuekang Pharmaceutical Group Co.,Ltd. Address before: 100176 No. 6, Hongda Middle Road, Beijing economic and Technological Development Zone, Beijing Co-patentee before: Beijing Yuantong Kangbai Pharmaceutical Co.,Ltd. Patentee before: Yuekang Pharmaceutical Group Co.,Ltd. |
|
TR01 | Transfer of patent right |